TMCnet News
Adaptive Biotechnologies and Collaborators to Highlight Clinical Relevance of Measuring Residual Disease in Blood Cancers at ASH 2017Adaptive Biotechnologies, the leader in using next-generation sequencing (NGS) to detect minimal/measurable residual disease (MRD) in blood cancers, and its collaborators will present 22 studies, including a late-breaker presentation, at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, December 9-12. Data presented at ASH will demonstrate how Adaptive's clonoSEQ® Assay to measure MRD, the cancerous cells remaining in the body after treatment, can inform clinical care in patients with B and T cell lymphoid malignancies. Additionally, at ASH, Adaptive and its collaborators will present data from studies utilizing the company's research-based immunosequencing platform, immunoSEQ™, to identify potential biomarkers of response to therapy. "MRD is increasingly viewed as a critical endpoint in lymphoid cancers used to assess a patient's response to cancer treatment and evaluate disease burden over time. At Adaptive, we are excited to see the growing use of this endpoint to support clinical trials and patient management," said Charles Sang, Senior Vice President of Diagnostics. "We leveraged our foundational immunosequencing platform to develop the clonoSEQ Assay which provides a highly sensitive and standardized determination of residual disease in patients with lymphoid malignancies." clonoSEQ, the first clinical application of Adaptive's pioneering immunosequencing platform, is helping to set a new standard for assessment of minimal residual disease in the clinic. It will be featured in a late breaker presentation, 5 orals and 7 posters. Data will be presented across a range of cancers -- 9 multiple myeloma, 1 peripheral T-cell lymphoma, 1 mantle cell lymphoma, 1 chronic lymphocytic leukemia, 1 follicular lymphoma. Abstracts of importance include:
Below is a full list of clonoSEQ and immunoSEQ related abstracts that will be presented at ASH this year. clonoSEQ Oral Abstract and Poster Presentation Highlights: Saturday, December 9, 2017
Oral Presentation, Abstract #154 Initial
Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma:
5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II
Study
Poster Presentation, Abstract #1824 Daratumumab
in Combination with Pomalidomide and Dexamethasone for RRMM Patients
with =2 Prior Lines of Therapy: Updated Analysis of MMY1001
Poster Presentation, Abstract #1852 Daratumumab,
Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for
Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of
Overall Survival in Castor
Poster Presentation, Abstract #1883 Daratumumab,
Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in
RRMM Based on Prior Treatment History, Renal Function, and Cytogenetic
Risk: Subgroup Analyses of Pollux Sunday, December 10, 2017
Oral Presentation, Abstract #435 Minimal
Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial
Oral Presentation, Abstract #496 A
Multicenter, Phase II Study of Ibrutinib Plus FCR As Frontline Therapy
for Younger CLL Patients Time: 5:15 - 5:30 PM Location: Bldg B, Lvl 5, Murphy BR 3-4 (Georgia World Congress Center)
Poster Presentation, Abstract #2728 Next-Generation
Sequencing Based Monitoring of Circulating-Tumor DNA in Untreated
Peripheral T-Cell Lymphoma
Poster Presentation, Abstract #3145 Daratumumab,
Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in
RRMM: Updated Efficacy and Safety Analysis of Castor Monday, December 11, 2017
Oral Presentation, Abstract #739 Daratumumab,
Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and
Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM):
Updated Efficacy and Safety Analysis of Pollux
Poster Presentation, Abstract #4533 High
Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged
Survival for the Overall Patient Population in the Phase 2 KRd Plus
Autologous Stem Cell Transplantation MMRC Trial
Poster Presentation, Abstract #4685 Measurable
Residual Disease (MRD) Testing in Multiple Myeloma Using an Improved
Testing Technology: Population Impact Tuesday, December 12, 2017
Late Breaker Presentation: LBA-4
Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and
Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in
Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for
Transplant (ALCYONE) immunoSEQ Abstract and Poster Presentation Highlights: Saturday, December 9, 2017
Poster Presentation, Abstract #1898 Quantifying
the Size and Diversity of the Human Alloresponse Via High-Throughput T
Cell Receptor Sequencing
Poster Presentation, Abstract #2069 Novel
Human Anti-HLA-Bw4 and B61 Monoclonal Antibodies Kill Malignant B Cells
Via CDC/ADCC While Sparing Normal Peripheral Blood Cells Sunday, December 10, 2017
Poster Presentation, Abstract #2454 Surveillance
of the Immune Repertoire of Aplastic Anemia Patients Using Deep
Sequencing
Poster Presentation, Abstract #2734 Longitudinal
Analyses of the Genomic, Transcriptomic, and T-Cell Repertoire in
Diffuse Large B-Cell Lymphoma Demonstrates Changes in Signaling and
Immune Recognition at Relapse
Poster Presentation, Abstract #2771 Intratumoral
G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients
with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100
Alone and in Combination with Pembrolizumab Monday, December 11, 2017
Oral Presentation, Abstract #649 Results
from a Phase 1/2 Study of Brentuximab Vedotin in Combination with
Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
Oral Presentation, Abstract #728 The
Tumor Microenvironment Is Independently Prognostic of Conventional and
Clinicogenetic Risk Models in Follicular Lymphoma
Oral Presentation, Abstract #825 The
T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL
Treated with R-CHOP: An Observational Study from a Prospective Clinical
Trial
Poster Presentation, Abstract #4506 Day
90 Post-Allogeneic Hematopoietic Cell Transplantation T Cell Receptor
Diversity Level Correlates with Risk of Relapse in Patients with
Multiple Myeloma About Minimal/Measurable Residual Disease Minimal/measurable residual disease (MRD) in hematologic malignancies refers to cancer cells that remain in the body of a person with cancer after treatment. In the case of clonoSEQ this includes ALL and MM. These cells can be present at levels undetectable by traditional morphologic, microscopic examination of blood, bone marrow or a lymph node biopsy. Sensitive molecular technologies, such as next-generation sequencing utilized by the Adaptive Biotechnologies clonoSEQ Assay, may be employed to facilitate the reliable detection of MRD at levels below the limits of traditional assessment. About the clonoSEQ® Assay The Adaptive Biotechnologies clonoSEQ Assay enables physicians to utilize a molecular, next-generation sequencing-based minimal/measurable residual disease (MRD) detection method. The clonoSEQ Assay detects and quantifies DNA sequences found in malignant cells which can be tracked throughout treatment. This robust assay provides consistent, accurate measurement of disease burden which potentially allows physicians to visualize response to treatment over time. The clonoSEQ assay is not approved or cleared by the FDA and is currently available in a CLIA-certified laboratory. clonoSEQ test results should only be used taking into account all available clinical information and should not be used as the sole determinant of patient care and management. About the immunoSEQ Platform Adaptive's immunoSEQ Platform helps researchers make discoveries in areas such as oncology, autoimmune disorders, infectious diseases and basic immunology. The immunoSEQ Assays can identify millions of T- and B-cell receptors from a single sample in exquisite detail. Offered as a Service or Kit, immunoSEQ Assays provide quantitative, reproducible sequencing results along with access to powerful, easy-to-use analysis tools. The immunoSEQ Assays are for research use only and are not for use in diagnostic procedures. About Adaptive Biotechnologies® Adaptive Biotechnologies is a pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive's mission is to translate immunosequencing discoveries into clinical diagnostics and therapeutics to improve patient care. For more information, please visit adaptivebiotech.com. Some studies and presentations referenced in this release may have received financial support or sponsorship from Adaptive Biotechnologies. View source version on businesswire.com: http://www.businesswire.com/news/home/20171208005425/en/ |